Compare IBRX & AG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBRX | AG |
|---|---|---|
| Founded | 2014 | 1979 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | 2015 | 2004 |
| Metric | IBRX | AG |
|---|---|---|
| Price | $7.24 | $15.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $12.57 | ★ $21.92 |
| AVG Volume (30 Days) | 9.4M | ★ 10.1M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.12% |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,288,000.00 | N/A |
| Revenue This Year | $88.59 | $24.41 |
| Revenue Next Year | $131.15 | $10.68 |
| P/E Ratio | ★ N/A | $143.01 |
| Revenue Growth | ★ 668.31 | N/A |
| 52 Week Low | $1.95 | $7.97 |
| 52 Week High | $12.43 | $32.00 |
| Indicator | IBRX | AG |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 38.75 |
| Support Level | $6.69 | $10.46 |
| Resistance Level | $8.46 | $17.72 |
| Average True Range (ATR) | 0.42 | 0.76 |
| MACD | -0.09 | -0.06 |
| Stochastic Oscillator | 38.93 | 24.73 |
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
First Majestic Silver Corp is in the business of production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. The company owns four producing mines in Mexico, consisting of the Santa Elena Silver/Gold Mine, the San Dimas Silver/Gold Mine, the Los Gatos Silver Mine, and the La Encantada Silver Mine. It also owns the Jerritt Canyon Gold Mine in Nevada, USA. Additionally, the firm holds interests in the San Martin Silver Mine and the Del Toro Silver Mine, and several exploration-stage projects. The majority of the company's revenues are from the sale of precious metals contained in dore and concentrate form. It generates maximum revenue from the sale of silver, followed by gold, zinc, copper, and other metals.